Polymorphous light eruption treated with omalizumab

Photodermatology, Photoimmunology & PhotomedicineVolume 39, Issue 1 p. 85-86 LETTER Polymorphous light eruption treated with omalizumab Ana Orbea Sopeña, Corresponding Author Ana Orbea Sopeña [email protected] Department of Dermatology, Hospital Universitario Cruces, Barakaldo, Spain Correspondence Ana Orbea Sopeña, Department of Dermatology, Hospital Universitario Cruces, Barakaldo, Spain. Email: [email protected]Search for more papers by this authorAida Aramburu González, Aida Aramburu González Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this authorManuel Pascual Ares, Manuel Pascual Ares Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this authorJesús Gardeazabal Garcia, Jesús Gardeazabal Garcia orcid.org/0000-0001-5938-0835 Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this author Ana Orbea Sopeña, Corresponding Author Ana Orbea Sopeña [email protected] Department of Dermatology, Hospital Universitario Cruces, Barakaldo, Spain Correspondence Ana Orbea Sopeña, Department of Dermatology, Hospital Universitario Cruces, Barakaldo, Spain. Email: [email protected]Search for more papers by this authorAida Aramburu González, Aida Aramburu González Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this authorManuel Pascual Ares, Manuel Pascual Ares Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this authorJesús Gardeazabal Garcia, Jesús Gardeazabal Garcia orcid.org/0000-0001-5938-0835 Department of Dermatology, Hospital Universitario Cruces, Barakaldo, SpainSearch for more papers by this author First published: 24 June 2022 https://doi.org/10.1111/phpp.12814Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Kadurina M, Kazandjieva J, Bocheva G. Immunopathogenesis and management of polymorphic light eruption. Dermatol Ther. 2021; 34(6): e15167. doi:10.1111/dth.15167 10.1111/dth.15167 PubMedWeb of Science®Google Scholar 2Chinthrajah RS, Galli SJ. Omalizumab in "non–IgE-mediated" diseases. J Allergy Clin Immunol. 2021; 147(4): 1207-1208. doi:10.1016/j.jaci.2020.10.033 10.1016/j.jaci.2020.10.033 CASPubMedWeb of Science®Google Scholar 3Lembo S, Raimondo A. Polymorphic light eruption: What's new in pathogenesis and management. Front Med. 2018; 5: 252. doi:10.3389/fmed.2018.00252 10.3389/fmed.2018.00252 Web of Science®Google Scholar 4Guntern P, Eggel A. Past, present, and future of anti-IgE biologics. Allergy. 2020; 75(10): 2491-2502. doi:10.1111/ALL.14308 10.1111/ALL.14308 PubMedWeb of Science®Google Scholar Volume39, Issue1January 2023Pages 85-86 ReferencesRelatedInformation